ELI Zgłoszenia SEC - ELIZABETH N J GEN IMPT BDS 2011- Raport roczny, oświadczenie o pełnomocnictwie, Prospekt

Podstawowe statystyki

CIK

1053369

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ELIZABETH N J GEN IMPT BDS 2011

SEC Filings (Chronological Order)

Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.

June 1, 2026	EX-99.1	Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product Exhibit 99.1 Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product NORTHVALE, N.J. – June 1, 2026 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announ
June 1, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 29, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 29, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS INC /NV/ ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction
April 14, 2026	LETTER	LETTER April 14, 2026 Carter Ward Chief Financial Officer Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, New Jersey 07647 Re: Elite Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended March 31, 2025 Filed June 30, 2025 File No. 001-15697 Dear Carter Ward: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and ade
April 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS, INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdictio
April 2, 2026	EX-99.1	Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets NORTHVALE, N.J. – April 2, 2026 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methado
March 18, 2026	CORRESP	March 18, 2026 Troutman Pepper Locke LLP 3000 Two Logan Square Eighteenth and Arch Streets Philadelphia, PA 19103 March 18, 2026 VIA EDGAR U.
March 4, 2026	LETTER	LETTER March 4, 2026 Carter Ward Chief Financial Officer Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, New Jersey 07647 Re: Elite Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended March 31, 2025 Filed June 30, 2025 File No. 001-15697 Dear Carter Ward: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. Please re
February 17, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite P
February 17, 2026	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST Northvale, NJ – February 17, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company de
February 17, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 17, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 17, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdic
November 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite
November 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 14, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 14, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS INC /NV/ ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdic
November 14, 2025	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 ended September 30, 2025 and Provides Conference Call Information Conference Call Scheduled for Monday, November 17 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 ended September 30, 2025 and Provides Conference Call Information Conference Call Scheduled for Monday, November 17 at 11:30 AM EST Northvale, NJ – November 14, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche g
November 12, 2025	EX-99.1	Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL® Exhibit 99.1 Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL® NORTHVALE, N.J. – November 12, 2025 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a
November 12, 2025	EX-99.1	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Frid Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025 Northvale, NJ – November 10, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialt
November 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 12, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 12, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS INC /NV/ ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdic
November 12, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS INC /NV/ ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisd
November 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS INC /NV/ ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdic
November 10, 2025	EX-99.1	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Frid Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025 Northvale, NJ – November 10, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialt
August 14, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdicti
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite Pharm
August 14, 2025	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Northvale, NJ – August 14, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic pro
August 8, 2025	EX-99.1	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025 Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, Aug Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025 Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, August 14, 2025 Northvale, NJ – August 8, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceut
August 8, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 8, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdictio
June 30, 2025	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT Northvale, NJ – June 30, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results
June 30, 2025	EX-10.24	Amendment to Hakim Employment Agreement, dated September 13, 2023. Exhibit 10.24
June 30, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction
June 30, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite Pharmaceutic
June 30, 2025	EX-14.1	Code of Business Conduct and Ethics of Elite Pharmaceuticals, Inc. Exhibit 14.1
June 23, 2025	EX-99.1	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025 Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025 Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025 Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025 Northvale, NJ – June 23, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing ni
June 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 23, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 23, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction
June 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 16, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 16, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. ELITE PHARMACEUTICALS INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction
June 16, 2025	EX-99.1	Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study Exhibit 99.1 Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study NORTHVALE, N.J. – June 16, 2025 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undis
April 30, 2025	EX-99.1	Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets NORTHVALE, N.J. – April 30, 2025 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic version of Percocet® (oxycodone hydrochloride and acetaminoph
April 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 30, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 30, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ELITE PHARMACEUTICALS INC /NV/ Nevada 001-15697 22-3542636 (State or other jurisdictio
March 3, 2025	EX-99.1	Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line Exhibit 99.1 Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line Northvale, NJ – March 3, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus. The ne
March 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 28, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 28, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
February 13, 2025	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, NJ – February 13, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company engaged in the devel
February 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite P
February 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 13, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 13, 2025 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
December 26, 2024	EX-99.1	Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse® Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse® NORTHVALE, N.J. – December 26, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 m
December 26, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 26, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
December 2, 2024	EX-99.1	Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets NORTHVALE, N.J. – December 2, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic version of Norco® (hydrocodone bitartrate and acetaminoph
December 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 2, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 2, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer o
November 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 18, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 18, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
November 18, 2024	EX-99.1	Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse® Exhibit 99.1 Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse® NORTHVALE, N.J. – November 18, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for a
November 14, 2024	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 ended September 30, 2024 and Provides Conference Call Information Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 ended September 30, 2024 and Provides Conference Call Information Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, NJ – November 14, 2024: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company engaged in the dev
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite
November 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 14, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 14, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
October 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 October 10, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 October 10, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer o
October 10, 2024	EX-99.1	Elite Pharmaceuticals’ Generic Adderall® Receives Marketing Approval from the Israeli Ministry of Health Exhibit 99.1 Elite Pharmaceuticals’ Generic Adderall® Receives Marketing Approval from the Israeli Ministry of Health NORTHVALE, N.J. – October 10, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced the Israeli Ministry of Health approval for Elite’s generic version of Adderall®, an imme
October 7, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 October 7, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
October 7, 2024	EX-99.1	Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets NORTHVALE, N.J. – October 7, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic version of Tylenol® with Codeine (acetaminophen and
August 27, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 27, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commissio
August 27, 2024	EX-99.1	Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium NORTHVALE, N.J. – August 27, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic methotrexate sodium 2.5 mg tablets. Methotrexate sodium tablets are
August 14, 2024	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 ended June 30, 2024 and Provides Conference Call Information Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 ended June 30, 2024 and Provides Conference Call Information Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT Northvale, NJ – August 14, 2024: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company engaged in the development
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite Pharm
August 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
July 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-15697 Elite Pharmaceutic
July 1, 2024	EX-10.59	Asset Purchase Agreement, dated June 17, 2024, by and between the Company and Nostrum Laboratories Inc. Exhibit 10.59
July 1, 2024	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, NJ – July 1, 2024: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results f
July 1, 2024	EX-10.1	Elite Pharmaceuticals, Inc. Restated 2014 Equity Incentive Plan. Exhibit 10.1 ELITE PHARMACEUTICALS, INC. RESTATED 2014 EQUITY INCENTIVE PLAN SECTION 1 INTRODUCTION 1.1 Restatement. Elite Pharmaceuticals, Inc. hereby restates the Elite Pharmaceuticals, Inc. 2014 Equity Incentive Plan (the “Plan”) for certain officers, employees, consultants, and directors of the Company. 1.2 Purposes. The purposes of the Plan are to provide the officers, employees, consultants,
July 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 1, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 1, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of in
July 1, 2024	S-8	As filed with the Securities and Exchange Commission on July 1, 2024 As filed with the Securities and Exchange Commission on July 1, 2024 Registration No.
July 1, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Elite Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.00
June 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 17, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 17, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of i
June 5, 2024	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 1, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of in
June 5, 2024	EX-16.1	Mazars USA letter dated June 5, 2024 Exhibit 16.1 June 5, 2024 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Elite Pharmaceuticals, Inc. (the “registrant”) under Item 4.01 of its Form 8-K dated June 5, 2024 and are in agreement with the statements therein concerning Mazars USA LLP. We have no basis to agree or disagree with other statements of t
May 20, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of in
May 20, 2024	EX-99.1	Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate Exhibit 99.1 Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate NORTHVALE, N.J. – May 20, 2024 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for gener
March 28, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Elite Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.00
March 28, 2024	S-8	As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No.
March 28, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Elite Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.00
March 28, 2024	S-8	As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No.
March 28, 2024	EX-99.1	Elite Pharmaceuticals, Inc. 2024 Equity Incentive Plan, incorporated by reference to Exhibit 99.1 to the Form S-8 filed with the SEC on March 28, 2024. Exhibit 99.1 ELITE PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN Elite Pharmaceuticals, Inc., a Nevada corporation, sets forth herein the terms of its 2024 Equity Incentive Plan, as follows: 1. PURPOSE The Plan is intended to enhance the Company’s and its Affiliates’ ability to attract and retain highly qualified employees, officers, Non-Employee Directors, and Consultants, and to motivate such
February 28, 2024	LETTER	LETTER United States securities and exchange commission logo February 28, 2024 Carter Ward Chief Financial Officer ELITE PHARMACEUTICALS INC /NV/ 165 Ludlow Avenue Northvale, NJ 07647 Re: ELITE PHARMACEUTICALS INC /NV/ Form 10-K for the Fiscal Year Ended March 31, 2023 Filed June 29, 2023 File No.
February 20, 2024	CORRESP	Troutman Pepper Hamilton Sanders LLP Troutman Pepper Hamilton Sanders LLP 400 Berwyn Park, 899 Cassatt Road Berwyn, PA 19312-1183 troutman.
February 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 14, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 14, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
February 14, 2024	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST Northvale, NJ – February 14, 2024: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the develop
February 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTI
January 22, 2024	LETTER	LETTER United States securities and exchange commission logo January 22, 2024 Carter Ward Chief Financial Officer ELITE PHARMACEUTICALS INC /NV/ 165 Ludlow Avenue Northvale, NJ 07647 Re: ELITE PHARMACEUTICALS INC /NV/ Form 10-K for the Fiscal Year Ended March 31, 2023 Filed June 29, 2023 Form 10-Q for the Six Months Ended September 30, 2023 Filed November 14, 2023 File No.
December 26, 2023	EX-99.1	Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant Exhibit 99.1 Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant NORTHVALE, N.J. – December 26, 2023 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced the US Food and Drug Administration’s (FDA) acceptance
December 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 26, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 26, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
December 12, 2023	EX-99.1	Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR® to Marketing Partner Prasco, LLC Exhibit 99.1 Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR® to Marketing Partner Prasco, LLC NORTHVALE, N.J. – December 12, 2023 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced the first shipment of generic Adderall XR® to its distribution and marketing part
December 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 12, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 12, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
November 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 14, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUT
November 14, 2023	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST Northvale, NJ – November 14, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the deve
September 25, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 September 25, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
September 25, 2023	EX-99.1	Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product Exhibit 99.1 Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product NORTHVALE, N.J. – September 25, 2023 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on Au
September 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 September 7, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 September 7, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
September 7, 2023	EX-10.1	Employment Agreement, dated September 5, 2023, between Elite Pharmaceuticals, Inc. and Carter Ward, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September 7, 2023. Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT This agreement (“Agreement”) is made on September 5, 2023, by and between Elite Pharmaceuticals, Inc., a Nevada corporation (“Company”), and Carter Ward (“Executive”). WHEREAS, Company desires Executive to be the Company’s Chief Financial Officer (“CFO”) and Executive desires to provide employment services to Company in such a capacity and in accord
September 7, 2023	EX-99.1	Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer Exhibit 99.1 Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer Northvale, NJ – September 7, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr.
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS
August 14, 2023	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 15 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 15 at 11:30 AM EDT Northvale, NJ – August 14, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company engaged in the development, man
August 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
July 31, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PH
July 17, 2023	EX-16.1	Buchbinder Letter Dated July 17, 2023, incorporated by reference to Exhibit 16 to the Current Report on Form 8-K filed with the SEC on July 17, 2023. Exhibit 16.1 July 17, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Ladies and Gentlemen: We have read Elite Pharmaceuticals, Inc.’s statements included under Item 4.01 of its Form 8-K filed on July 17, 2023 and we agree with such statements concerning our firm. Sincerely, BUCHBINDER TUNICK & COMPANY LLP 150 Clove Road, 5th Floor ● Little Falls, NJ 07424 ●
July 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 11, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 11, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of i
June 29, 2023	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT Northvale, NJ – June 29, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of i
June 29, 2023	10-K	Consent of Buchbinder Tunick & Company LLP, Independent Registered Public Accounting Firm* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS, INC. (Exact Name of Registrant as Speci
May 3, 2023	EX-99.1	Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer Exhibit 99.1 Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer Northvale, NJ – May 3, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegri
May 3, 2023	EX-10.1	Employment Agreement, dated April 27, 2023, between Elite Pharmaceuticals, Inc. and Mark Pellegrino, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 3, 2023 Exhibit 10.1 April 27, 2023 Personal and Confidential Mark N. Pellegrino, CPA Dear Mark, This offer letter (the “Agreement”) shall confirm our understanding as to the terms of your employment with Elite Laboratories, Inc., a Delaware corporation (the “Company”). 1. Commencing on May 1, 2023, you shall become an employee of the Company as the Chief Financial Officer. Your job responsibilities will
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 3, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 3, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of inc
April 20, 2023	EX-99.1	Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product Exhibit 99.1 Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product NORTHVALE, N.J. – April 20, 2023 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undiscl
April 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 20, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 20, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 28, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 28, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commiss
February 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 14, 2023 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
February 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTI
February 14, 2023	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST Northvale, NJ – February 14, 2023: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche
December 22, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 22, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
December 22, 2022	EX-99.1	Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist Exhibit 99.1 Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist NORTHVALE, N.J. ? December 22, 2022 ? Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclose
November 28, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 28, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 28, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
November 15, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 15, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
November 15, 2022	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 ended September 30, 2022, and Provides Conference Call Information Conference Call Scheduled for Tuesday, November 15 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 ended September 30, 2022, and Provides Conference Call Information Conference Call Scheduled for Tuesday, November 15 at 11:30 AM EST Northvale, NJ ? November 15, 2022: Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUT
November 10, 2022	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
November 2, 2022	EX-99.1	Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study Exhibit 99.1 Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study NORTHVALE, N.J. ? November 2, 2022 ? Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed extended-release generic
November 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 2, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commissi
September 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 September 7, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
September 7, 2022	EX-10.1	Employment Agreement, dated September 5, 2022, between Elite Pharmaceuticals, Inc. and Kirko Kirkov, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September 7, 2022. Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT This agreement (?Agreement?) is made on September 5, 2022, by and between Elite Pharmaceuticals, Inc., a Nevada corporation (?Company?), and Kirko Kirkov (?Executive?). WHEREAS, Company desires Executive to be the Company?s Chief Commercial Officer (?CCO?) and Executive desires to provide employment services to Company in such a capacity and in acco
August 26, 2022	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 26, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
August 15, 2022	EX-10.3	Loan and Security Agreement, dated April 1, 2022, by and among East West Bank, Elite Pharmaceuticals, Inc. and Elite Laboratories, Inc., incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q, for the period ended June 30, 2022 and filed with the SEC on August 15, 2022. Exhibit 10.3
August 15, 2022	EX-10.2	Agreement for Sale and Purchase of Real Estate, dated April 8, 2022, by and between Clyde Wesp and Margaret Wesp as trustees of the Wesp Family Joint Living Trust UTD November 19, 2015 and the Company, incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q, for the period ended June 30, 2022 and filed with the SEC on August 15, 2022. Exhibit 10.2
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS
August 15, 2022	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 16 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 16 at 11:30 AM EDT Northvale, NJ ? August 15, 2022: Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic p
August 15, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 15, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
June 29, 2022	EX-99.1	Elite Pharmaceuticals Receives FDA Approval for Generic Sabril® Exhibit 99.1 Elite Pharmaceuticals Receives FDA Approval for Generic Sabril? NORTHVALE, N.J. ? June 29, 2022 ? Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic
June 29, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS, INC. (Exact Name of Registrant as Spe
June 29, 2022	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT EX-99.1 2 ex99-1.htm Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT Northvale, NJ – June 29, 2022: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic produ
June 29, 2022	EX-10.56	License, Supply, and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Lannett Company, Inc, dated October 18, 2021.* Exhibit 10.56 September 20, 2021 Lannett Company, Inc. 9000 State Road Philadelphia, PA 19136 Re: Letter of Agreement between Elite Pharmaceuticals, Inc. and Lannett Company, Inc. for Dantrolene (?Dantrolene Renewal Letter?) Mr. Block, Lannett Company, Inc., a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (?Lannett?), and Elite Pharmaceuticals, Inc.
June 29, 2022	EX-10.57	License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd. (Or Akiva, Israel), dated December 6, 2021, incorporated by reference to Exhibit 10.57 to the Annual Report on Form 10-K for the period ended March 31, 2022, filed with the SEC on June 29, 2022. CONFIDENTIAL Exhibit 10.57 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED SUPPLY & DISTRIBUTION AGREEMENT This Supply & Distribution Agreement (?Agreement?) is effective as of the Effective Date by and between: ELITE PHARMACEUTICALS, INC., with its offices located
June 29, 2022	EX-10.59	License, Supply, and Distribution Agreement by and between Elite Pharmaceuticals and Lannett, Inc., dated July 20, 2021* Exhibit 10.59 EXPLANATORY NOTE: [*] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED License, SUPPLY and Distribution Agreement FOR VIGABATRIN Elite pharmaceuticals, inc., elite laboratories, inc., - and - LANNETT COMPANY, Inc. Dated as of July 20, 2021 EXPLANATORY NOTE: [*] INDICATES T
June 29, 2022	EX-10.55	License, Supply, and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Lannett Company, Inc, dated October 18, 2021.* Exhibit 10.55 September 20, 2021 Lannett Company, Inc. 9000 State Road Philadelphia, PA 19136 Re: Letter of Agreement between Elite Pharmaceuticals, Inc. and Lannett Company, Inc. (?Amphetamine Renewal Letter?) Mr. Block, Lannett Company, Inc., a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (?Lannett?), and Elite Pharmaceuticals, Inc. a Nevada corpo
June 29, 2022	EX-10.58	February 18, 2022 Retention Agreement with Douglas Plassche, incorporated by reference to Exhibit 10.58 to the Annual Report on Form 10-K for the period ended March 31, 2022, filed with the SEC on June 29, 2022. Exhibit 10.58 EXPLANATORY NOTE: [*] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED February 18, 2022 Personal and Confidential Douglas Plassche * *** Dear Doug, This letter agreement (the ?Agreement?) shall confirm our understanding as to the terms of your continuing employment with E
June 29, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 27, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of i
June 29, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of i
May 11, 2022	EX-99.1	Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer Exhibit 99.1 Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer Northvale, NJ ? May 11, 2022: Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer (CFO), effective May 16, 2022, succ
May 11, 2022	EX-10.1	Employment Agreement, dated May 5, 2022, between Elite Pharmaceuticals, Inc. and Robert Chen Exhibit 10.1 May 5, 2022 Personal and Confidential Robert Chen 11 Barnyard Court Plainsboro, NJ 08536 Dear Robert, This offer letter (the ?Agreement?) shall confirm our understanding as to the terms of your employment with Elite Laboratories, Inc., a Delaware corporation (the ?Company?). 1. Commencing on May 16th, 2022, you shall become an employee of the Company as the Chief Financial Officer. Yo
May 11, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commission F
April 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 18, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commission
April 4, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 4, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of i
April 4, 2022	EX-99.1	Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline Exhibit 99.1 Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline NORTHVALE, N.J. ? April 4, 2022 ? Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that together with Elite?s co-development partner, Praxgen Pharmaceuticals LLC, formerly SunGen Pharma
February 15, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 14, 2022 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
February 15, 2022	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST Northvale, NJ ? February 14, 2022: Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic
February 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2021 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTI
December 9, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 9, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer o
December 2, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 2, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer o
December 2, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 2, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer o
November 15, 2021	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT Northvale, NJ ? August 16, 2021: Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic pr
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUT
November 15, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 16, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
August 16, 2021	EX-10.1	Master Development and License Agreement for Products Between Elite Pharmaceuticals, Inc. and Mikah Pharma LLC, effective as of June 10, 2021.(Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10), incorporated by reference to the 10-Q for the period ended June 30, 2021 and filed with the SEC on August 16, 2021. EX-10.1 2 ex10-1.htm Exhibit 10.1 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND MIKAH PHARMA LLC This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated June 10,
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS
August 16, 2021	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT Northvale, NJ ? August 16, 2021: Elite Pharmaceuticals, Inc. (?Elite? or the ?Company?) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic pr
August 16, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 16, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commissio
June 22, 2021	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2021 [ ] TRANSITION REP 10-K/A 1 form10-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE
June 14, 2021	EX-10.54	July 29, 2019 Amendment To The License, Supply And Distribution Agreement Between Elite Pharmaceuticals, Inc./Elite Laboratories, Inc. And Lannett Company, Inc. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.54 4 f10k2021ex10-54elitepharma.htm JULY 29, 2019 AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT BETWEEN ELITE PHARMACEUTICALS, INC./ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC. Exhibit 10.54 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED.
June 14, 2021	EX-10.52	Employment Agreement with Douglas Plassche, incorporated by reference to Exhibit 10.52 to the Annual Report on Form 10-K, filed with the SEC on June 14, 2021. Exhibit 10.52 July 20, 2013 Personal and Confidential Douglas Plassche 18 Sunrise Circle Clinton, NJ 08809 Dear Doug, This letter agreement (the ?Agreement?) shall confirm our understanding as to the terms of your employment with Elite Laboratories, Inc., a Delaware corporation (the ?Company?). 1. Commencing on April 12, 2013, you shall become an employee of the Company as a Vice President of Oper
June 14, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS, INC
June 14, 2021	EX-10.53	June 21, 2019 Retention Agreement with Douglas Plassche.*+ EX-10.53 3 f10k2021ex10-53elitepharma.htm JUNE 21, 2019 RETENTION AGREEMENT WITH DOUGLAS PLASSCHE Exhibit 10.53 June 21, 2019 Personal and Confidential Douglas Plassche Dear Doug, This letter agreement (the “Agreement”) shall confirm our understanding as to the terms of your continuing employment with Elite Laboratories, Inc., a Delaware corporation (the “Company”). In recognition of the value Eli
June 14, 2021	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT EX-99.1 2 ea142694ex99-1elitephar.htm PRESS RELEASE Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT Northvale, NJ – June 14, 2021: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company
June 14, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 14, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commission
May 5, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 5, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commission Fi
May 5, 2021	EX-99.1	Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules Exhibit 99.1 Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules NORTHVALE, N.J. ? May 4, 2021 ? Elite Pharmaceuticals, Inc. ("Elite" or the ?Company") (OTCBB: ELTP) announced today that its distribution and marketing partner Prasco, LLC (?Prasco?), has launched Elite?s generic Loxapine capsules. Elite entered
April 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 26, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of
April 29, 2021	EX-99.1	Elite Pharmaceuticals, Inc. Names Marc Bregman as Chief Financial Officer EX-99.1 3 ea140117ex99-1elitepharma.htm PRESS RELEASE DATED APRIL 29, 2021 Exhibit 99.1 Elite Pharmaceuticals, Inc. Names Marc Bregman as Chief Financial Officer Northvale, NJ – April 29, 2021: Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, announced today that Marc Bregman, CPA, has been
April 29, 2021	EX-10.1	Employment Agreement, dated April 26, 2021, between Elite Pharmaceuticals, Inc. and Marc Bregman EX-10.1 2 ea140117ex10-1elitepharma.htm EMPLOYMENT AGREEMENT, DATED APRIL 26, 2021, BETWEEN ELITE PHARMACEUTICALS, INC. AND MARC BREGMAN Exhibit 10.1 April 26, 2021 Personal and Confidential Marc Bregman Dear Marc, This offer letter (the “Agreement”) shall confirm our understanding as to the terms of your employment with Elite Laboratories, Inc., a Delaware corporation (the “Company”). 1. Commenci
April 12, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 ea139323-8kelitepharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 7, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or o
March 12, 2021	LETTER	LETTER United States securities and exchange commission logo March 12, 2021 Nasrat Hakim Chief Executive Officer Elite Pharmaceuticals Inc.
March 12, 2021	TEXT-EXTRACT	TEXT-EXTRACT United States securities and exchange commission logo March 12, 2021 Nasrat Hakim Chief Executive Officer Elite Pharmaceuticals Inc.
February 22, 2021	CORRESP	Troutman Pepper Hamilton Sanders LLP Troutman Pepper Hamilton Sanders LLP 400 Berwyn Park, 899 Cassatt Road Berwyn, PA 19312-1183 troutman.
February 16, 2021	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2021 Ended December 31, 2020 and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 17 at 11:30 AM EST EX-99.1 2 ea135829ex99-1elitepharma.htm PRESS RELEASE DATED FEBRUARY 16, 2021 Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2021 Ended December 31, 2020 and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 17 at 11:30 AM EST Northvale, NJ – February 16, 2021: Elite Pharmaceuticals, Inc. (“Elite” or the
February 16, 2021	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTI
February 16, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 16, 2021 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporation) (Commiss
February 9, 2021	TEXT-EXTRACT	TEXT-EXTRACT United States securities and exchange commission logo February 9, 2021 Nasrat Hakim Chief Executive Officer Elite Pharmaceuticals Inc.
February 9, 2021	LETTER	LETTER United States securities and exchange commission logo February 9, 2021 Nasrat Hakim Chief Executive Officer Elite Pharmaceuticals Inc.
November 16, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUT
November 16, 2020	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results For The Second Quarter of Fiscal Year 2021 Ended September 30, 2020 and Provides Conference Call Information Conference Call Scheduled for Tuesday, November 17 at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results For The Second Quarter of Fiscal Year 2021 Ended September 30, 2020 and Provides Conference Call Information Conference Call Scheduled for Tuesday, November 17 at 11:30 AM EST Northvale, NJ – November 16, 2020: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing and ma
November 16, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 16, 2020 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer
September 1, 2020	SC 13D/A	ELTP / Elite Pharmaceuticals, Inc. / Hakim Nasrat A - AMENDMENT NO. 2 TO FORM SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Elite Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28659T200 (CUSIP Number) Richard Feiner, Esq. Wall Street Plaza 88 Pine Street, 22nd Floor New York, NY 10005 (646) 822-1170 (Name, Address and Telephone Number of Pe
August 27, 2020	8-K	Unregistered Sales of Equity Securities - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 27, 2020 (August 24, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorpo
August 17, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2020 (August 14, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorpo
August 17, 2020	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results For The First Quarter Of Fiscal Year 2021 Ended June 30, 2020 And Provides Conference Call Information Financials for First Quarter of Fiscal Year 2021 ended June 30, 2020 will be released August Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results For The First Quarter Of Fiscal Year 2021 Ended June 30, 2020 And Provides Conference Call Information Financials for First Quarter of Fiscal Year 2021 ended June 30, 2020 will be released August 14, 2020 Northvale, NJ – August 14, 2020: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutica
August 14, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS
August 14, 2020	EX-10.57	Series J Preferred Stock and Series J Common Stock Purchase Warrant anti-dilution waiver * Exhibit 10.57 Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, NJ 07647 Attn: Carter Ward Dear Carter, Elite Pharmaceuticals, Inc. has entered into an equity line purchase agreement with Lincoln Park Capital Fund LLC (the “2020 LPC Agreement”) to replace the prior equity line purchase agreement with Lincoln Park that expired on July 1, 2020 (the “2017 LPC Agreement”). Pursuant to the terms
July 31, 2020	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-2 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 31, 2020 (August 1, 2013) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorp
July 31, 2020	EX-10.1	August 1, 2013, Asset Purchase Agreement between the Company and Mikah Pharma LLC. Exhibit 10.1 ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT (“Agreement”), dated August 1, 2013 (the “Effective Date”), between Mikah Pharma LLC a limited liability company organized under the laws of the State of Delaware ( “Seller”) and Elite Laboratories, Inc., a corporation incorporated under the laws of the State of Delaware (“Buyer”). Buyer and Seller are each “Party” to this Agreement an
July 27, 2020	424B3	ELITE PHARMACEUTICALS, INC. 262,500,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-239874 PROSPECTUS ELITE PHARMACEUTICALS, INC. 262,500,000 Shares of Common Stock This prospectus relates to the sale of up to 262,500,000 shares of our common stock by Lincoln Park Capital Fund, LLC, or Lincoln Park or the selling stockholder. The shares of common stock being offered by the selling stockholder have been or may be issued to Linc
July 23, 2020	CORRESP	- ELITE PHARMACEUTICALS, INC. 165 Ludlow Avenue Northvale, NJ 07647 July 23, 2020 Securities and Exchange Commission 100 F Street, NE Washington, DC 20002 Re: Elite Pharmaceuticals, Inc. Registration Statement on Form S-3 (SEC filing No. 333-239874) Acceleration Request Requested Date: July 27, 2020 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securitie
July 22, 2020	LETTER	LETTER United States securities and exchange commission logo July 22, 2020 Carter Ward Chief Financial Officer Elite Pharmaceuticals, Inc.
July 22, 2020	TEXT-EXTRACT	- United States securities and exchange commission logo July 22, 2020 Carter Ward Chief Financial Officer Elite Pharmaceuticals, Inc.
July 15, 2020	S-3	As filed with the Securities and Exchange Commission on July 15, 2020 As filed with the Securities and Exchange Commission on July 15, 2020 Registration Statement No.
July 15, 2020	COVER	Securities and Exchange Commission RICHARD FEINER ATTORNEY AT LAW 88 Pine Street Of Counsel 22nd Floor Silverman Shin New York, New York 10005 & Byrne PLLC (646) 822-1170 Fax: (917) 720-0863 E-Mail RFeiner@Silverfirm.
July 9, 2020	EX-10.1	Purchase Agreement between the Company and Lincoln Park Capital LLC dated July 8, 2020, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated July 9, 2020 and filed with the SEC on July 9, 2020. Exhibit 10.1 Execution Version PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of July 8, 2020, by and between ELITE PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inve
July 9, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 9, 2020 (July 8, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS
July 9, 2020	EX-10.2	Registration Rights Agreement between the Company and Lincoln Park Capital LLC dated July 8, 2020, incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, dated July 9, 2020 and filed with the SEC on July 9, 2020. Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of July 8, 2020, by and between ELITE PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not
June 30, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2020 (June 29, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (I
June 30, 2020	10-K	Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS, INC
June 30, 2020	EX-10.52	Employment Agreement with Douglas Plassche * EX-10.52 3 f10k2020ex10-52elite.htm EMPLOYMENT AGREEMENT WITH DOUGLAS PLASSCHE Exhibit 10.52 July 20, 2013 Personal and Confidential Douglas Plassche 18 Sunrise Circle Clinton, NJ 08809 Dear Doug, This letter agreement (the “Agreement”) shall confirm our understanding as to the terms of your employment with Elite Laboratories, Inc., a Delaware corporation (the “Company”). 1. Commencing on April 12
June 30, 2020	EX-10.54	July 29, 2019 Amendment To The License, Supply And Distribution Agreement Between Elite Pharmaceuticals, Inc./Elite Laboratories, Inc. And Lannett Company, Inc., incorporated by reference to Exhibit 10.54 to the Annual Report on Form 10-K for the period ended March 31, 2020 and filed with the SEC on June 29, 2020 (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.54 5 f10k2020ex10-54elite.htm JULY 29, 2019 AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT BETWEEN ELITE PHARMACEUTICALS, INC./ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC. Exhibit 10.54 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. FIRST
June 30, 2020	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for The Fiscal Year Ended March 31, 2020 and Provides Conference Call Information Conference Call Scheduled for Tuesday, June 30th at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for The Fiscal Year Ended March 31, 2020 and Provides Conference Call Information Conference Call Scheduled for Tuesday, June 30th at 11:30 AM EDT Northvale, NJ – June 29, 2020: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced resul
June 30, 2020	EX-4.6	Description of Common Stock, incorporated by reference to Exhibit 4.6 to the Annual Report on Form 10-K, filed with the SEC on June 29, 2020 Exhibit 4.6 Description of Common Stock The following summary description of the common stock of Elite Pharmaceuticals, Inc. (“we”, “our” or “us”) is based on the provisions of our amended and restated articles of incorporation as amended (“Articles of Incorporation”), as well as our amended and restated bylaws (“Bylaws”), and the applicable provisions of the Nevada Revised Statutes (“Nevada Law”)
June 30, 2020	EX-10.53	June 21, 2019 Retention Agreement with Douglas Plassche.* Exhibit 10.53 June 21, 2019 Personal and Confidential Douglas Plassche Dear Doug, This letter agreement (the “Agreement”) shall confirm our understanding as to the terms of your continuing employment with Elite Laboratories, Inc., a Delaware corporation (the “Company”). In recognition of the value Elite places on your past and continued service to the Company, we are pleased to offer you an incent
June 24, 2020	EX-3.1	Certificate of Amendment to Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, dated June 24, 2020 and filed with the SEC on June 24, 2020. EX-3.1 2 ea123419ex3-1elitepharma.htm AMENDMENT TO THE ARTICLES OF INCORPORATION OF ELITE PHARMACEUTICALS, INC. Exhibit 3.1
June 24, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 ea123419-8kelitepharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 24, 2020 (June 23, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-354
May 11, 2020	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden
April 29, 2020	DEF 14A	- DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden
April 23, 2020	EX-3.2	Amended and Restated By-Laws of the Company, incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K dated April 23, 2020 and filed with the SEC on April 23, 2020. Exhibit 3.1(ii) AMENDED AND RESTATED BYLAWS OF ELITE PHARMACEUTICALS, INC. (a Nevada corporation) The foregoing are the Amended and Restated Bylaws of ELITE PHARMACEUTICALS, INC., a Nevada corporation (the “Corporation”), effective as of April 22, 2020. ARTICLE I Offices Section 1.01. PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at 165 Ludlow Avenu
April 23, 2020	8-K	Financial Statements and Exhibits, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 22, 2020 (April 22, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission
April 17, 2020	PRE 14A	ELTP / Elite Pharmaceuticals, Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT PRE 14A 1 ea120752-pre14aelite.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Chec
February 26, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 26, 2020 (February 20, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commi
February 10, 2020	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2020 Ended December 31, 2019 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 11th at 11:00 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2020 Ended December 31, 2019 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 11th at 11:00 AM EST Northvale, NJ – February 10, 2020: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing niche
February 10, 2020	10-Q	ELTP / Elite Pharmaceuticals, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTI
February 10, 2020	EX-10.45	License, Supply And Distribution Agreement effective March 6, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA, incorporated by reference to Exhibit 10.45 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February 10, 2020. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.45 3 f10q1219ex10-45elitepharma.htm LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EFFECTIVE MARCH 6, 2019 BY AND BETWEEN ELITE PHARMACEUTICALS, INC., AND ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC., USA Exhibit 10.45 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY D
February 10, 2020	EX-10.49	Asset Purchase Agreement executed January 16, 2020 by and between the Company and Nostrum Laboratories Inc., incorporated by reference to Exhibit 10.49 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February 10, 2020. Exhibit 10.49 ASSET PURCHASE AGREEMENT BY AND BETWEEN Elite Pharmaceuticals, Inc. AND NOSTRUM LABORATORIES INC. DATED AS OF \ November 13, 2019 This document is not intended to create, nor will it be deemed to create, a legally binding or enforceable offer or agreement of any type or nature, unless and until the duly authorized and approved execution of this document by the parties and the deliver
February 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 10, 2020 (February 10, 2020) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commi
February 10, 2020	EX-10.51	Asset Purchase Agreement executed January 16, 2020 by and between the Company and Nostrum Laboratories Inc., incorporated by reference to Exhibit 10.49 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February 10, 2020. Exhibit 10.51 ASSET PURCHASE AGREEMENT BY AND BETWEEN Elite Pharmaceuticals, Inc. AND NOSTRUM LABORATORIES INC. DATED AS OF December 16, 2019 This document is not intended to create, nor will it be deemed to create, a legally binding or enforceable offer or agreement of any type or nature, unless and until the duly authorized and approved execution of this document by the parties and the delivery
February 10, 2020	EX-10.44	August 1, 2018 Amendment to the Glenmark Pharmaceuticals Inc. USA License, Supply and Distribution Agreement, incorporated by reference to Exhibit 10.44 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February 10, 2020. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)).of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.44 2 f10q1219ex10-44elitepharma.htm AUGUST 1, 2018 AMENDMENT TO THE GLENMARK PHARMACEUTICALS INC. USA LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT Exhibit 10.44 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. FIRST AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUT
February 10, 2020	EX-10.50	January 2, 2020 Amendment to the Glenmark Pharmaceuticals Inc. USA License, Supply and Distribution Agreement, incorporated by reference to Exhibit 10.50 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February 10, 2020. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.50 5 f10q1219ex10-50elitepharma.htm JANUARY 2, 2020 AMENDMENT TO THE GLENMARK PHARMACEUTICALS INC. USA LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT Exhibit 10.50 EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. SECOND AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIB
December 12, 2019	8-K	Financial Statements and Exhibits, Regulation FD Disclosure, Regulation FD Disclosure 8-K 1 f8k121119elitepharma.htm PRESS RELEASE DATED DECEMBER 12, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 12, 2019 (December 11, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its cha
December 12, 2019	EX-99.1	Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall XR® Exhibit 99.1 Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall XR® NORTHVALE, N.J. – December 12, 2019 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing its own generic products, partenered generic products and proprietary abuse-deterrent opioids, today announced that it received approval from the U
December 5, 2019	EX-3.1	Amendment to the Articles of Incorporation of Elite Pharmaceuticals, Inc. Exhibit 3.1 Elite Pharmaceuticals, Inc. NVID: NV20121008448 5. Information being changed: Section 4.1 of Article IV is amended and, as amended, reads as follows: “4.1. Authorized Capital Stock. The aggregate number of shares which this Corporation shall have authority to issue is One Billion Four Hundred Forty Five Million Fifteen Thousand (1,445,015,000) shares, consisting of (a) One Billion Four
December 5, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 December 5, 2019 (December 4, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commiss
November 19, 2019	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 19, 2019 (November 13, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commi
November 12, 2019	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2020 Ended September 30, 2019 and Provides Conference Call Information Conference Call Scheduled for Wednesday, November 13th at 11:00 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2020 Ended September 30, 2019 and Provides Conference Call Information Conference Call Scheduled for Wednesday, November 13th at 11:00 AM EST Northvale, NJ – November 12, 2019: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing ab
November 12, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k111219elitepharma.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 November 12, 2019 (November 12, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-354
November 12, 2019	10-Q	ELTP / Elite Pharmaceuticals, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUT
October 18, 2019	DEFA14A	ELTP / Elite Pharmaceuticals, Inc. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS. DEFA14A 1 defa14a1019elitepharma.htm DEFINITIVE ADDITIONAL MATERIALS. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No ) Filed by the Registrant x Filed by a Party other than the Registrant
October 10, 2019	DEF 14A	ELTP / Elite Pharmaceuticals, Inc. DEF 14A - - DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden
September 27, 2019	PRE 14A	ELTP / Elite Pharmaceuticals, Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confiden
September 12, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 September 12, 2019 (September 10, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of i
September 12, 2019	EX-99.1	Elite Pharmaceuticals Receives FDA Approval for Codeine and Acetaminophen Combo Exhibit 99.1 Elite Pharmaceuticals Receives FDA Approval for Codeine and Acetaminophen Combo NORTHVALE, N.J. – September 12, 2019 – Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbre
August 9, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k080919elitepharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 August 9, 2019 (August 9, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-354
August 9, 2019	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2020 Ended June 30, 2019 and Provides Conference Call Information Conference Call Scheduled for Monday, August 12th at 10:00 AM EDT EX-99.1 2 f8k080919ex99-1elitepharma.htm PRESS RELEASE DATED AUGUST 9, 2019 Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2020 Ended June 30, 2019 and Provides Conference Call Information Conference Call Scheduled for Monday, August 12th at 10:00 AM EDT Northvale, NJ – August 9, 2019: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (
August 9, 2019	10-Q	ELTP / Elite Pharmaceuticals, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS
June 21, 2019	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2019 and Provides Conference Call Information Conference Call Scheduled for Monday, June 24h at 11:30 AM EDT Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2019 and Provides Conference Call Information Conference Call Scheduled for Monday, June 24h at 11:30 AM EDT Northvale, NJ – June 21, 2019: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic
June 21, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 24, 2019 (June 21, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (I
June 21, 2019	EX-10.50	License, Supply and Distribution Agreement effective March 6, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA, incorporated by reference to Exhibit 10.50 to the Annual Report on Form 10-K for the period ended March 31, 2019 and filed with the SEC on June 21, 2019 (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.50 3 f10k2019ex10-50elitepharma.htm LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EFFECTIVE MARCH 6, 2019 BY AND BETWEEN ELITE PHARMACEUTICALS, INC., AND ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC., USA Exhibit 10.50 EXPLANATORY NOTE: [**] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DI
June 21, 2019	EX-10.49	License, Supply and Distribution Agreement effective April 9, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA, incorporated by reference to Exhibit 10.49 to the Annual Report on Form 10-K for the period ended March 31, 2019 and filed with the SEC on June 21, 2019 (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). EX-10.49 2 f10k2019ex10-49elitepharma.htm LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EFFECTIVE APRIL 9, 2019 BY AND BETWEEN ELITE PHARMACEUTICALS, INC., AND ELITE LABORATORIES, INC. AND LANNETT COMPANY, INC., USA Exhibit 10.49 EXPLANATORY NOTE: [**] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DI
June 21, 2019	EX-10.51	Development Agreement effective December 3, 2018 by and between Mikah Pharma LLC and Elite Laboratories, Inc., incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K for the period ended March 31, 2019 and filed with the SEC on June 21, 2019 (portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). Exhibit 10.51 EXPLANATORY NOTE: [**] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. DEVELOPMENT AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND MIKAH PHARMA This DEVELOPMENT AGREEMENT (the “Agreement”), dated December 3, 2018 (the “Effective Date”) between Mikah Pharma LLC
June 21, 2019	EX-21	Subsidiaries of the Company, incorporated by reference to Exhibit 21 to the Annual Report on Form 10-K, for the period ended March 31, 2019 and filed with the SEC on June 21, 2019. EX-21 5 f10k2019ex21elite.htm SUBSIDIARY OF THE COMPANY Exhibit 21 Subsidiary of the Company Elite Laboratories, Inc., a Delaware corporation.
June 21, 2019	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED MARCH 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTICALS, INC
June 14, 2019	NT 10-K	ELTP / Elite Pharmaceuticals, Inc. NT 10-K - - NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001 – 15697 CUSIP NUMBER 28659T200 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran
March 11, 2019	EX-99.1	Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall® Exhibit 99.1 Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall® NORTHVALE, N.J. – March 11, 2019 – Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today that it has entered into a license, supply, and distribution agreement (“Agreement”) with Lannett Company, Inc. (“Lannett”). Lannett will be the exclusive U.S. distribut
March 11, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 March 11, 2019 (March 7, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of incorporat
February 12, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 February 12, 2019 (February 11, 2019) Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction of inc
February 12, 2019	EX-99.1	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2019 Ended December 31, 2018 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 12th at 11:30 AM EST Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2019 Ended December 31, 2018 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 12th at 11:30 AM EST Northvale, NJ – February 11, 2019: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-
February 11, 2019	10-Q	ELTP / Elite Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 001-15697 ELITE PHARMACEUTI

ELI / ELIZABETH N J GEN IMPT BDS 2011 - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

Podstawowe statystyki

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?